The Role of Combination or Coformulation Products in the Treatment of Type 2 Diabetes


Most patients with type 2 diabetes will require multiple pharmacologic agents as their disease progresses. For second-line therapy and beyond, clinicians now select among several treatment options—including insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 agonists, and sodium–glucose cotransporter 2 inhibitors. Although combination or coformulation products can simplify treatment regimens, identifying the best therapies for individual patients can still be daunting. Come explore proven strategies for effective second-line therapies for type 2 diabetes.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Review updates to the 2018 American Diabetes Association Standards of Medical Care in Diabetes.
  2. Describe the mechanism of action and unique features of the various classes of medications that are recommended as second-line therapies for type 2 diabetes.  
  3. Discuss contraindications and adverse effect considerations when recommending combination therapy for glycemic control. 
  4. Given a patient case, select among available combination or coformulation treatment options for add-on therapy.
Jennifer Trujillo,
University of Colorado Denver
Susan Cornell, PHARMD,BS, FAPhA
Learning Level: Level 2
Track: Clinical Patient Care and Services
Session Time Slot(s): 
Sunday, March 18
3:30 PM - 5:00 PM
Music City Center - Room 104C-D
ACPE Pharmacist: 0202-0000-18-053-L05-P
CEUs Pharmacist: 0.15
Activity Type: